Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00607113 | Avastin (Bevacizumab) and RAD001 (Everolimus) in Advanced Low or Intermediate Grade Neuroendocrine Carcinoma | PHASE2 | COMPLETED | 41 | — | — | Jan 1, 2008 | Oct 1, 2011 | Jul 18, 2013 | 1 | United States |
Tumor blood flow (ml/min/100gm) determined by functional computed tomography (CT). Functional computed tomography (CT) at baseline, after first and third cycles (21 day cycles). Change (percentage) calculated as tumor blood flow measured at baseline compared to tumor blood flow measurement taken at end of Cycle 1, week 3 (21 days), and again at end of Cycle 3, Week 9 (63 days).
| Arm | Type | Description |
|---|---|---|
| Avastin | EXPERIMENTAL | Cycle 1 (First 3 weeks of study) - Avastin 15 mg/kg intravenous (IV) |
| Avastin + RAD001 | EXPERIMENTAL | Cycle 2: Avastin 15 mg/kg intravenous (IV) every 3 weeks + RAD001 10 mg orally daily for 3 weeks |
| RAD001 | EXPERIMENTAL | Cycle 1 (First 3 weeks of study)- RAD001 10 mg orally daily for 21 Days |
| Name | Type | Description |
|---|---|---|
| Avastin | DRUG | 15 mg/kg By Vein Over 90 Minutes Every 21 Days |
| RAD001 | DRUG | 10 mg By Mouth Daily For 21 Days |
Inclusion Criteria: 1. Patients must have histologically or cytologically confirmed low or intermediate grade neuroendocrine carcinoma. Patients with neuroendocrine tumors associated with MEN1 syndrome will be eligible. 2. Patients must have at least one measurable site of disease according to Resp...